Clinical features and prognostic factors of 89 cases of myeloid sarcoma
10.3760/cma.j.cn421203-20200624-00207
- VernacularTitle:89例髓系肉瘤临床特征及预后因素分析
- Author:
Ping TANG
1
;
Zhenkun DONG
;
Rong GUO
;
Haiqiong WANG
;
Runqing LU
;
Xinsheng XIE
;
Hui SUN
;
Ling SUN
;
Dingming WAN
;
Yanfang LIU
;
Zhongxing JIANG
Author Information
1. 郑州大学第一附属医院血液内科 450052
- Keywords:
Hematopoietic stem cell transplantation;
Myeloid sarcoma;
Decitabine
- From:
Chinese Journal of Organ Transplantation
2021;42(3):173-176
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical characteristics, treatment and prognosis of myeloid sarcoma(MS).Methods:From January 2010 to May 2019, clinical data were reviewed for 89 MS cases. Age, gender, site of onset, type, comorbid diseases, lymphatic characteristics and disease remission status were analyzed. And 1-year survival rates were explored for different treatments including whether or not chemotherapy, transplantation and using hypomethylated drugs(HMAs)for maintenance after transplantation.Results:Among them, 21 cases had the data of chromosome karyotypic analysis and next generation sequencing and 8 patients underwent allogeneic hematopoietic stem cell transplantation(allo-HSCT). The 1-year overall survival rates(OS)of primary MS, MS with intramedullary disease and MS relapse after leukemic remission were 16.0%, 37.5% and 36.9% respectively( P=0.013). The 1-year OS of local treatment(surgical resection, intrathecal injection and local radiotherapy), chemotherapy plus local treatment and chemotherapy plus allo-HSCT was 0, 28.1% and 72.9% respectively( P=0.003). After two courses of treatment, the 1-year OS of patients with complete and incomplete remissions were 34.9% and 10.0% respectively( P=0.008). Half(4/8)MS patients relapsed within 1 year after transplantation and had a short survival.Three patients received decitabine after HSCT and all of them survived for a long time. Conclusions:Chemotherapy plus HSCT is efficacious for MS. Decitabine maintenance treatment after transplantation may prolong recurrence-free survival. However, a larger sample size is required for further clinical verifications.
